Growth in the Asia-Pacific Region
While North America currently holds the largest share, the Anti-VEGF Market is poised for explosive growth in the Asia-Pacific region. This is driven by several factors, including a massive and aging population, rising rates of chronic diseases like diabetes, and improving healthcare infrastructure. Countries like China, Japan, and India are seeing a rapid increase in the number of patients with wet AMD and DME, creating a huge and underserved patient population.
Governments in many Asia-Pacific nations are also playing a supportive role through increased healthcare spending and the inclusion of anti-VEGF drugs in national reimbursement programs. This is making the treatments more accessible to a broader population and attracting significant investment from global pharmaceutical companies. The vast market potential in this region is a major factor shaping the future growth of the anti-VEGF market.